Australia markets open in 5 hours 51 minutes

Grifols, S.A. (GIFLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
8.460.00 (0.00%)
At close: 10:43AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.46
Open9.12
Bid0.00 x 0
Ask0.00 x 0
Day's range8.46 - 8.46
52-week range7.46 - 15.80
Volume66
Avg. volume2,019
Market cap5.379B
Beta (5Y monthly)0.68
PE ratio (TTM)84.60
EPS (TTM)0.10
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date03 June 2021
1y target estN/A
  • PR Newswire

    Grifols 2023 Annual Report on Form 20-F filed with the SEC

    Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").

  • GlobeNewswire

    Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

    The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants whi

  • Reuters

    Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper

    MADRID (Reuters) -Spanish drug maker Grifols, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday. Grifols' market value has shed billions of euros since short-sheller Gotham City Research released three reports in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.